UPCC Phase II Clinical trials of PhotoDynamic

John H. Glick, MD
Director, Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 10 de febrero del 2004

Share article


Imprima English

Dear Colleague:

We are conducting Phase II trials of photodynamic therapy at the Abramson Cancer Center of the University of Pennsylvania. As you may know, photodynamic therapy is a new locoregional form of cancer treatment. It has been approved by the FDA for the treatment of esophageal cancer. Based upon a prior Phase I study conducted at the National Cancer Institute, we are now evaluating this treatment modality in patients with peritoneal carcinomatatosis.

Patients with disseminated intraperitoneal malignancies, including refractory ovarian cancer, GI cancer, sarcomas and peritoneal mesothelioma may be eligible for one of our trials. We are also conducting trials using photodynamic therapy in patients with lung and prostate cancer. Patients first receive the photosensitizer, Photofrin, which appears to accumulate in cancer cells to a greater degree than in normal tissues. At this point some patients will undergo maximal debulking surgery. Patients will then be treated with visible light from a laser. The combination of the laser light and the photosensitizer leads to a photochemical reaction that destroys the cancer cells.

If you have patients who might be eligible for this trial, please contact:

Stephen Hahn, MD
Assistant Professor of Radiation Oncology
Abramson Cancer Center of the University of Pennsylvania
Phone: (215) 662-7296
E-mail: hahn@xrt.upenn.edu
Stephen C. Rubin, MD
Director, Division of Gynecologic Oncology
Abramson Cancer Center of the University of Pennsylvania
Phone: (215) 662-3318
E-mail: srubin@mail.obgyn.upenn.edu
Douglas Fraker, MD
Chief, Surgical Oncology
Abramson Cancer Center of the University of Pennsylvania
Phone: (215) 662-7866
E-mail: fraker@mail.med.upenn.edu
Debbie Smith, RN
Photodynamic Therapy Nurse
Abramson Cancer Center of the University of Pennsylvania
Phone: (215) 662-6694
Email: smith@xrt.upenn.edu

Sincerely,
John H. Glick, MD

Imprima English
News
Researchers say vaccine trial suggests 'clinically meaningful benefit' and plan further research

Feb 1, 2010 - Treatment with a prostate-specific antigen-targeted poxviral vaccine substantially improves overall survival among metastatic prostate cancer patients, according to the results of a phase II study published online Jan. 25 in the Journal of Clinical Oncology.


Frequently Asked Questions


Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información